

Original Article

Cite this article: Aksoy GK, Yapar D, Koyun NS, and Doğan ÇS (2022) Comparison of ESHG₂₀₁₆ and AAP₂₀₁₇ hypertension guidelines in adolescents between the ages of 13 and 16: effect of body mass index on guidelines. *Cardiology in the Young* **32**: 94–100. doi: [10.1017/S1047951121003450](https://doi.org/10.1017/S1047951121003450)

Received: 22 February 2021
Revised: 7 July 2021
Accepted: 31 July 2021
First published online: 23 August 2021

Keywords:

Hypertension; adolescents; HT guidelines; kappa analysis

Author for correspondence:

Dr G. Kaya Aksoy, University of Health Sciences, Antalya Training and Research Hospital, Antalya, Turkey.
E-mail: gkayaaksoy@gmail.com

Comparison of ESHG₂₀₁₆ and AAP₂₀₁₇ hypertension guidelines in adolescents between the ages of 13 and 16: effect of body mass index on guidelines

Gülşah Kaya Aksoy¹ , Dilek Yapar², Nevin Semerci Koyun¹ and Çağla Serpil Doğan¹

¹University of Health Sciences, Antalya Training and Research Hospital, Antalya, Turkey and ²Gazi Üniversitesi, Ankara, Turkey

Abstract

Objective: The diagnosis of hypertension in adolescents aged ≥ 13 and < 16 years is based on the percentile according to age, gender, and height in the European Society of Hypertension guidelines guideline; whereas, the American Academy of Pediatrics guideline uses blood pressure above 130/80 mmHg as a single criterion. Therefore, this study aimed to evaluate the compatibility of these two guidelines in adolescents aged ≥ 13 and < 16 years. **Methods:** This study was designed by retrospectively screening the records of 395 adolescents with both office and 24-hour ambulatory blood pressure measurements. Each blood pressure measurement was classified according to both the ESHG2016 and AAP2017 guidelines. Patients were divided into three subgroups according to body mass index. Cohen's kappa analysis was used to evaluate the agreement between the two guidelines. **Results:** The majority of adolescents were normotensive according to both guidelines, 55.9% by ESHG2016 and 43.1% by AAP2017. For the whole group, the frequency of hypertension was 32.4% with ESHG2016 and 34.4% with AAP2017; while, in obese patients, hypertension frequencies were 38.8% and 43.3%, respectively. The diagnosis of hypertension was demonstrated with the two guidelines, and there was significant agreement at a substantial level, both for the obese subgroup and the whole study group (kappa value = 0.738 and 0.785, respectively). The frequency of white-coat hypertension was higher with the AAP2017 guideline (28.1% versus 16.2%, $p < 0.001$). **Conclusion:** With our experience in this single-centre study, it seems that both the AAP2017 and the ESHG2016 guidelines can be used in the diagnosis of hypertension in adolescents.

Early diagnosis of hypertension and recommendations of lifestyle changes are important strategies in detection and treatment, especially in primary health care. It is accepted that the first traces of the pathology leading to cardiovascular diseases in adulthood begin during the childhood and adolescent periods.^{1,2} In the last century, the frequency of HT has been gradually increasing in childhood.^{3,4} In a meta-analysis evaluating 47 studies, the prevalence of HT in children 19 years or younger was 4.00% (95% CI = 3.29–4.78%).³ The same study evaluated the prevalence of HT according to weight and determined that the prevalence of HT was 5.27% in obese, 4.99% in overweight, and 1.9% in normal-weight patients.³

Considering the concerns in the diagnosis of children, new updates have been made to paediatric HT guidelines in the past few years.^{5,6} In 2016, the European Society of Hypertension guidelines was revised based on the reference data of the United States Task Force.⁵ The most important innovation in the ESHG₂₀₁₆ guideline, the diagnosis of HT in adolescents 16 years or older was determined as systolic blood pressure ≥ 140 mmHg and/or diastolic BP ≥ 90 mmHg. In the ESHG₂₀₁₆ guideline, BP percentiles based on age, gender, and height stated in the Fourth Report for the Diagnosis of HT in Childhood continued to be used.⁷ Thereafter, in 2017, the United States Task Force guideline was renewed by the American Academy of Pediatrics.⁶ In the AAP₂₀₁₇ guideline, the use of percentiles according to age, gender, and height was recommended until the age of 13; for adolescents aged 13 and over, HT diagnosis was based on blood pressure $> 130/80$ mmHg. Besides, only normal-weight individuals were taken into consideration in the AAP₂₀₁₇ guideline; overweight and obese children were ignored.⁶

It is noteworthy that, for adolescents aged at least 13 years and less than 16 years, the ESHG₂₀₁₆ guideline recommends the use of percentile based on age, gender, and height; whereas, the AAP₂₀₁₇ guideline determines a fixed cut-off value. Based on this difference, this study aimed to evaluate the agreement of HT diagnosis with the ESHG₂₀₁₆ and AAP₂₀₁₇ guidelines in adolescents aged ≥ 13 and < 16 years. We also sought to determine whether the frequency of HT in obese adolescents varies with the use of either guideline.

Methods

The study included adolescents aged at least 13 years and less than 16 years who presented to the University of Health Sciences, Antalya Training and Research Hospital, Pediatric Nephrology Department, Antalya, Turkey, with suspicion of HT between January, 2017 and December, 2019. Patients with 24-hour ambulatory blood pressure measurements in addition to office BP measurements were included in the study. Patients without anthropometric measurements and patients with antihypertensive drug use were excluded from the study. Ethics committee approval was received from the University of Health Sciences, Antalya Training, and Research Hospital (22.10.2020-311).

Anthropometric measurements

Height was measured to the nearest 0.1 cm using a portable wall-mounted stadiometer and weight was measured to the nearest 0.1 kg. Percentile values for height were obtained using reference values for Turkish children.⁸ Body mass index was calculated as body weight (kg) divided by height (m) squared (kg/m^2). Adolescents were classified into three subgroups according to BMI z score; BMI z score ≤ 1.5 (normal), BMI z score 1.5–2 (overweight), and BMI z score ≥ 2 (obese).

Office blood pressure measurements

Automated oscillometric devices were used on the upper arm (with anthropometrically suitable cuff size) for office BP measurement. Oscillometric device used in the study was validated by the biomedical department of our hospital before the study started. All measurements were performed in the seated position, at 5-minute intervals, and by the same trained nurse. Three measurements were taken for each adolescent and an average of the values from the second and third were used. Office BP for adolescents at each screen was classified by both ESHG₂₀₁₆ guidelines and AAP₂₀₁₇ guidelines.^{5,6} According to the ESHG₂₀₁₆ guidelines, office BP has to be persistently in the ≥ 95 th percentile for gender, age, and height was defined as HT. Systolic BP and/or diastolic BP between ≥ 90 th percentile and < 95 th percentile was defined as high-normal BP. Hypertension was also classified as stage 1 (95th percentile to the 99th percentile and 5 mmHg) and stage 2 (> 99 th percentile and 5 mmHg).⁵

According to the AAP₂₀₁₇ guidelines, elevated BP was defined as systolic BP 120–129 mmHg and diastolic BP less than 80 mmHg, while HT was defined as at least 130/80 mmHg for adolescents aged 13 years and older. Hypertension was also classified as stage 1 (BP between 130/80 mmHg and 139/89 mmHg) and stage 2 (at least 140/at least 90 mmHg) in these patients.⁶

Twenty-four-hour ambulatory blood pressure measurements

Twenty-four hour ambulatory blood pressure was measured on the non-dominant arm, with cuff size selected according to the mid-arm circumference, on the same day as office blood pressure. The oscillometric Space Labs 90207 monitors (SpaceLabs Inc., Redmond, Washington, USA) were used for records. ABPM recordings started at 9 am and continued until 9 am the next morning. Awake and sleep periods were separated using self-reported sleep and wake times. Blood pressure reading was obtained every 20 min during the awake period and every 30 min during the sleep period. Based on the European guidelines, records with at least 70% measurements (and at least seven times during sleep period) were

deemed to be suitable for inclusion; thus, all patients meeting these conditions were included in the study.⁹

Reference values for ABPM measurements provided by the German Working Group on Pediatric Hypertension.¹⁰ Four subgroups were created with office BP and ABPM measurements; normotension, hypertension, white-coat hypertension, and masked HT.^{11,12} The definitions of these definitions were presented in detail in Table 1.

Statistical analysis

Descriptive statistics were presented as frequency, percentage, mean, standard deviation, median, and interquartile range. The Shapiro–Wilk test, histogram, and Q-Q graphics were used for the evaluation of normality of distribution. The chi-square analysis was used in the analysis of relationships between categorical variables. For the comparison of continuous variables, the Student's t-test and one-way ANOVA were used with variables that showed normal distribution, while the Mann–Whitney U-test and Kruskal–Wallis were used in those with non-normal distribution. Pairwise comparisons were conducted by Tukey post hoc multiple comparison tests. McNemar–Bowker test was used to evaluate the change in the distribution of ABPM diagnosis. Cohen's kappa and overall accuracy were calculated to compare item agreements between ESHG₂₀₁₆ and AAP₂₀₁₇ guidelines. Cohen suggested the kappa result be interpreted as follows: values ≤ 0 indicating no agreement, 0.01–0.20 none to a slight agreement, 0.21–0.40 as fair, 0.41–0.60 as moderate, 0.61–0.80 as substantial, and 0.81–1.00 as almost-perfect agreement.¹³ Overall accuracy is the probability that an individual will be correctly classified by a test; that is, the sum of the true positives and true negatives divided by the total number of individuals tested.¹⁴ Statistical analyses were performed using the SPSS version 21.0 package program for Windows (IBM, Armonk, NY, USA). p values of < 0.05 were accepted to show statistical significance.

Results

A total of 2508 children and adolescents were admitted or referred with the suspicion of HT to the paediatric nephrology department during the study period. ABPM measurement was applied to 2124 (84.7%) of them, and 1729 of these children were excluded based on their age (< 13 or ≥ 16 years). A total of 395 adolescents (217 boys, 54.9%) with a mean age of 14.53 ± 0.85 years at the time of study inclusion were enrolled. The distribution of adolescents according to BMI was as follows: normal weight ($n = 224$, 56.7%), overweight ($n = 37$, 9.4%), obese ($n = 134$, 33.9%). The frequency of obesity was similar in boys and girls (32.7% versus 35.4%, $p = 0.652$). The mean age and height were similar between normal weight, overweight, and obese groups ($p = 0.057$ and $p = 0.064$, respectively). The characteristic features of the groups were presented in Table 2.

In the whole study population, mean systolic and diastolic BPs were 121.79 ± 12.40 and 73.87 ± 8.46 , respectively. While the mean systolic BP of obese adolescents was higher than those with normal weight; such a relationship was not observed in the comparison of diastolic BP ($p = 0.020$ and $p = 0.135$, respectively).

Categories of office blood pressure

The majority of adolescents were normotensive by both guidelines, 55.9% by ESHG₂₀₁₆ and 43.1% by AAP₂₀₁₇. The frequency of normotension, high-normal (elevated) BP, stage 1 HT, and stage 2 HT

Table 1. Office blood pressure and ambulatory blood pressure measurement definitions according to guidelines

Guidelines	Normotension	White-coat HT	Masked HT	Hypertension
ESHG ₂₀₁₆ guidelines ¹¹	Office BP < 95 th percentile and mean ABPM < 95 th percentile	Office BP ≥ 95 th percentile and mean ABPM < 95 th percentile	Office BP < 95 th percentile and mean ABPM ≥ 95 th percentile or ABPM > 130/80 mmHg	Office BP ≥ 95 th percentile and mean ABPM ≥ 95 th percentile or ABPM > 30/80 mmHg
AAP ₂₀₁₇ guidelines ¹²	Office BP < 130/80 mmHg and mean ABPM < 95 th percentile and BP load < 25%	Office BP > 130/80 mmHg and mean ABPM < 95 th percentile and BP load < 25%	Office BP < 130/80 mmHg and mean ABPM > 95 th percentile and BP load ≥ 25%	Office BP < 130/80 mmHg and mean ABPM > 95 th percentile and BP load ≥ 25%

AAP2017 = American Academy of Pediatrics guideline; ABPM = ambulatory blood pressure monitoring; BP = blood pressure; ESHG2016 = European Society of Hypertension guidelines; HT = hypertension.

Table 2. Demographic and blood pressure characteristics of the study group

Variables	Total (n = 395)	Normal BMI (n = 224)	Overweight (n = 37)	Obesity (n = 134)	p
Age (years)	14.53 ± 0.85	14.16 ± 0.83	14.74 ± 0.90	14.60 ± 0.85	0.057*
Sex, n (%)					0.829**
Male	217 (54.9)	126 (56.3)	20 (54.1)	71 (53.0)	
Female	178 (45.1)	98 (43.7)	17 (45.9)	63 (47.0)	
Weight (kg)	72.77 ± 22.51	59.03 ± 11.69	75.72 ± 12.84	94.98 ± 20.20	<0.001*
Height (cm)	165.32 ± 10.05	164.30 ± 10.22	166.08 ± 11.36	166.82 ± 9.21	0.064*
BMI (kg/m ²)	26.38 ± 7.04	21.73 ± 2.80	27.22 ± 1.31	33.92 ± 6.29	<0.001*
BMI Z-score	1.32 (1.32–2.36)	0.25 (–0.48–1.07)	1.72 (1.61–1.86)	2.73 (2.35–3.20)	<0.001***
Office SBP (mmHg)	121.79 ± 12.40	120.13 ± 12.22	121.65 ± 12.71	123.80 ± 12.72	0.027*
Office DBP (mmHg)	73.87 ± 8.46	73.07 ± 8.18	74.18 ± 9.77	74.95 ± 9.14	0.135*
24-hour SBP (mmHg)	115.39 ± 8.92	114.89 ± 8.60	114.21 ± 9.75	116.33 ± 9.67	0.264*
24-hour DBP (mmHg)	65.62 ± 6.64	66.27 ± 6.11	65.64 ± 10.45	64.61 ± 6.23	0.077*
24-hour MAP (mmHg)	88.41 ± 6.97	88.54 ± 6.60	87.89 ± 9.40	88.27 ± 7.09	0.846*
24-hour HR (bpm)	80.59 ± 9.83	80.32 ± 10.31	81.43 ± 12.62	81.65 ± 9.06	0.459*
Daytime SBP (mmHg)	117.13 ± 10.58	116.39 ± 11.22	116.05 ± 10.56	118.30 ± 9.77	0.226*
Daytime DBP (mmHg)	67.53 ± 6.99	68.10 ± 6.31	67.45 ± 10.70	66.58 ± 6.74	0.140*
Daytime MAP (mmHg)	90.23 ± 7.26	90.27 ± 6.72	89.78 ± 10.09	90.28 ± 7.25	0.926*
Daytime HR (bpm)	94.24 ± 10.21	83.80 ± 10.71	84.78 ± 11.96	85.39 ± 9.50	0.374*
Night-time SBP (mmHg)	109.15 ± 10.37	108.76 ± 9.32	108.33 ± 10.11	109.95 ± 12.21	0.530*
Night-time DBP (mmHg)	56.69 ± 7.73	60.24 ± 6.84	59.55 ± 10.86	58.63 ± 8.29	0.177*
Night-time MAP (mmHg)	82.12 ± 8.95	82.11 ± 8.91	81.80 ± 9.64	82.21 ± 8.88	0.971*
Night-time HR (bpm)	69.88 ± 11.48	69.19 ± 11.19	71.72 ± 15.31	70.53 ± 10.69	0.347*

BMI = body mass index; DBP = diastolic blood pressure; HR = heart rate; MAP = mean arterial blood pressure; SBP = systolic blood pressure.

The bold values are statistically significant.

*One-way ANOVA test.

**Chi-square test.

***Kruskal–Wallis test.

were 55.9%, 11.6%, 25.7%, 6.8% with the ESHG₂₀₁₆ and 43.1%, 22.5%, 26.6%, 7.8% with the AAP₂₀₁₇ guideline (Fig 1). The compatibility of ESHG₂₀₁₆ and AAP₂₀₁₇ guidelines was evaluated in the distribution of office blood pressure categories: there was significant agreement at a moderate level (kappa value = 0.609, $p < 0.001$). However, 40 (20.8%) of the adolescents diagnosed with normotension in the ESHG₂₀₁₆ guideline were in the elevated BP category as per the AAP₂₀₁₇ guideline. Also, 20 (43.5%) of the adolescents defined as high-normal BP in ESHG₂₀₁₆ were classified as stage 1 HT with AAP₂₀₁₇ (Table 3).

The distribution of office blood pressure categories in normal weight, overweight, and obese groups were shown in Figure 1.

The agreement of the ESHG₂₀₁₆ and AAP₂₀₁₇ guidelines in-office blood pressure categories was evaluated separately in normal weight, overweight, and obese groups (kappa values, respectively: 0.586, 0.512, and 0.664, the p -value for all <0.001) (Table 4).

In the whole study population, the frequency of HT was 32.4% ($n = 128$) and 34.4% ($n = 136$) according to ESHG₂₀₁₆ and AAP₂₀₁₇ guidelines, respectively. The frequency of HT was 28.6% in the normal-weight group, 32.4% in the overweight group, and 38.8% in the obese group using ESHG₂₀₁₆ criteria ($p = 0.046$). With the AAP₂₀₁₇ guidelines, these percentages were found as: 29.5%, 32.4%, and 43.3%, respectively, ($p = 0.009$). The compatibility of both guidelines in the diagnosis of HT was evaluated separately according to weight

Table 3. Distribution of office BP categories according to the HT guidelines

n (%)	AAP ₂₀₁₇				Total*
	Normotension	Elevated BP	Stage 1 HT	Stage 2 HT	
ESHG ₂₀₁₆					
Normotension	168 (76)	46 (20.8)	7 (3.2)	0	221 (55.9)
High-normal BP	2 (4.3)	24 (52.2)	20 (43.5)	0	46 (11.6)
Stage 1 HT	0	19 (18.8)	76 (75.3)	6 (5.9)	101 (25.7)
Stage 2 HT	0	0	2 (7.4)	25 (92.6)	27 (6.8)
Total	170 (43)	89 (22.5)	105 (26.6)	31 (7.8)	395 (100)

The bold values indicate the number of cases with the same classification for both guidelines.

*Column percentage (unless otherwise specified row percentage is presented).

Table 4. Evaluation of the agreement for the diagnosis of HT between ESHG 2016 and AAP 2017 guidelines

		Agreement (n)	Disagreement (n)	Overall Accuracy %	Kappa value	p	Degree of agreement
In all study group (n = 395)	Office HT diagnosis*	293	102	74.2%	0.609	<0.001	Moderate
	Office HT diagnosis**	349	46	88.4%	0.738	<0.001	Substantial
	ABPM diagnosis***	329	66	83.3%	0.746	<0.001	Substantial
Normal weight group (n = 224)	Office HT diagnosis*	165	59	73.7%	0.586	<0.001	Moderate
	Office HT diagnosis**	198	26	88.4%	0.718	<0.001	Substantial
	ABPM diagnosis***	184	40	82.14%	0.763	<0.001	Substantial
Overweight group (n = 37)	Office HT diagnosis*	25	12	67.6%	0.512	<0.001	Moderate
	Office HT diagnosis**	31	6	83.8%	0.630	<0.001	Substantial
	ABPM diagnosis***	29	8	78.3%	0.694	<0.001	Substantial
Obese group (n = 134)	Office HT diagnosis*	103	31	76.9%	0.664	<0.001	Substantial
	Office HT diagnosis**	120	14	89.6%	0.785	<0.001	Substantial
	ABPM diagnosis***	116	18	86.5%	0.803	<0.001	Perfect

AAP2017 = American Academy of Pediatrics guidelines 2017; ESHG2016 = European Society of Hypertension guidelines 2016.

*Categories for office HT diagnosis: Normotension/High-normal/Stage 1 HT/Stage 2 HT.

**Categories for office HT diagnosis: Normotension/HT.

***Categories for ABPM diagnosis: Normotension/White-coat HT/Masked HT/HT.




Figure 1. Distribution of office blood pressure categories in whole study group and grouped by weight status.




Figure 2. Distribution of ABPM diagnosis in whole study group according to AAP₂₀₁₇ and ESHG₂₀₁₆ guidelines.




Figure 3. Distribution of ABPM diagnosis in obese group according to AAP₂₀₁₇ and ESHG₂₀₁₆ guidelines.

groups (in addition to the analysis of the whole study population). The results showed that there were significant agreements at a substantial level in the whole group and also the subgroups (Table 4).

Distribution of 24-hour ambulatory blood pressure measurement categories

Systolic, diastolic, mean arterial BP, and heart rates obtained in ABPM were presented in Table 2. There were 136 adolescents (34.4%) with mean ABPM >95th and systolic/diastolic load $\geq 25\%$ according to the AAP₂₀₁₇ guideline, and 123 adolescents (31.1%) with mean ABPM ≥ 95 th percentile or ABPM >130/80 mm according to the ESHG₂₀₁₆ guideline. Adolescents were classified into separate groups using ABPM and office BP measurements; the frequency of HT, WCT, masked HT, and normotension obtained according to ESHG₂₀₁₆ and AAP₂₀₁₇ guidelines were shown in Figure 2. A total of 64 (16.2%) adolescents were classified as WCT with ESHG₂₀₁₆ criteria, whereas 111 (28.1%) adolescents were diagnosed with WCT using the AAP₂₀₁₇ criteria ($p < 0.001$). In contrast, the frequency of adolescents with normotension was higher in the ESHG₂₀₁₆ guidelines than in the AAP₂₀₁₇ guidelines (49.2% versus 37.0%, $p < 0.001$). There was no difference between the masked HT and HT frequency ($p = 0.163$ and 0.324 , respectively). The compatibility of the ESHG₂₀₁₆ and AAP₂₀₁₇ guidelines for ABPM diagnosis was evaluated in the whole study group and showed substantial agreement (kappa value = 0.746, $p < 0.001$).

In the ABPM diagnosis, the frequency of HT in obese adolescents was 29.2% with ESHG₂₀₁₆ guideline and 32.1% with AAP₂₀₁₇ guideline. Similar to the overall study population, the frequency of WCT was higher with the AAP₂₀₁₇ guideline (29.8% versus 20.8%, $p = 0.002$) and the frequency of normotension was higher with the ESHG₂₀₁₆ guideline in obese adolescents (44.8% versus 34.3%, $p < 0.001$) (Fig 3). The agreement of both guidelines for ABPM diagnoses was evaluated separately in the normal weight, overweight, and obese groups. This analysis demonstrated that there was significant agreement at a substantial level in the normal weight and overweight groups (kappa value = 0.763 and 0.694, respectively); whereas, the obese group showed perfect-level agreement (kappa value = 0.803) (Table 4).

Discussion

In this study, the frequency of HT in adolescents aged between 13 and 16 years was found to be 32.4% with the ESHG₂₀₁₆ guideline and 34.4% with the AAP₂₀₁₇ guideline. Our study found substantial agreement between the ESHG₂₀₁₆ and AAP₂₀₁₇ guidelines in the diagnosis of HT according to office BP measurements. Further, the moderate agreement was found in the comparison of office blood pressure categories. In particular, the diagnosis of elevated HT and stage 1 HT was higher in the AAP₂₀₁₇ guideline compared to the ESHG₂₀₁₆ guideline.

The results of a study evaluating 2957 children, 747 of whom were 13–15 years old, stated that the AAP₂₀₁₇ guideline found a higher percentage of high-normal and stage 1 HT than the ESHG₂₀₁₆ guideline.¹⁵ It is emphasised that this difference increases especially in boys and those over 13 years of age.¹⁵ Blood pressure measurements of 15,647 healthy children from National Health and Nutrition Examination Surveys between 1999 and 2014 were re-evaluated with the AAP₂₀₁₇ guideline; 381 patients had newly diagnosed HT and the HT staging of 524 patients worsened.¹⁶ In a study comparing the AAP₂₀₁₇ guideline with the 2004 Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents, the percentage of elevated HT for adolescents 13–15 years of age was higher with the AAP₂₀₁₇ guideline, but there was no increase in the frequency of hypertension.¹⁷ The same study evaluated the agreement of the AAP₂₀₁₇ HT guideline with the Fourth Report, and the kappa value and overall accuracy were determined to be good in older patients (0.85% and 92.6%).¹⁷

In this study, we found that the frequency of obesity was 33.9%. Both guidelines resulted in the determination of a higher frequency of HT in obese adolescents compared to those with normal weight. Throughout the world, the prevalence of childhood obesity has been increasing, especially in the last decade.^{18,19} Especially the effect of sedentary life on obesity is well known.²⁰ In our country, obesity prevalence was 9.8% and overweight prevalence was 23.2% in a cross-sectional study that included 1687 school-aged children.²¹ The frequency of obesity in this study was higher than the predicted prevalence for our country, possibly because our study population was selected from patients suspected to have hypertension. Besides, since obese children are at risk for HT, BP measurement is usually not neglected during the routine examinations of these patients.

In a study of 6137 obese and overweight children with a mean age of 10.8 ± 2.7 years, the prevalence of HT was 30.7% with the ESHG₂₀₁₆ guideline and 34.8% with the AAP₂₀₁₇ guideline.²² It was emphasised that the diagnosis of HT was 13% higher than ESHG₂₀₁₆ with the AAP₂₀₁₇ guideline, and this difference was increased especially in overweight children over 13 years of age.²² A multicentre randomised controlled study from China found that the prevalence of HT diagnosed with the AAP₂₀₁₇ guideline in obese children aged 13–17 years was 8.5% higher than the Fourth Report (34.0% versus 25.5%; $p < 0.001$).²³ In our study, the frequency of HT in obese adolescents was 43.3% with the AAP₂₀₁₇ guideline, 38.8% with the ESHG₂₀₁₆ guideline. The agreement between the AAP₂₀₁₇ guideline and ESHG₂₀₁₆ guideline in the diagnosis of hypertension was substantial in all normal weight, overweight and obese groups.

In the ABPM diagnosis, the frequency of WCT was significantly higher in the AAP₂₀₁₇ guidelines. Also, the frequency of normotension was observed more frequently with the ESHG₂₀₁₆ guidelines. This difference in the whole study group was also observed in the obese adolescent subgroup. The reason for the increase in the frequency of WCT with the AAP₂₀₁₇ guideline is quite feasibly associated with the fact that many patients' BP levels that were $>130/80$ mmHg in-office measurements were actually below the 95th percentile according to the ESHG₂₀₁₆ guidelines. Similarly to our study, Lurbe et al demonstrated that the frequency of WCT was higher with the AAP₂₀₁₇ guideline.¹⁴ In different studies, the frequency of WCT varies between 7% and 52% in patients referred for high BP.^{11,24,25} Venettacci et al evaluated the compatibility and inconsistency of both guidelines on ABPM diagnoses, and found that masked HT was prominent in the ESH guideline

and white coat HT was prominent in the AAP guideline.²⁶ Adult studies emphasise that approximately half of the patients with WCT had sustained HT at a 10-year follow-up.^{27,28}

In this study, the agreement between AAP₂₀₁₇ and ESHG₂₀₁₆ guidelines in the categories of ABPM diagnosis was evaluated, and the perfect level was found to be in the obese group. Among the ABPM diagnoses, the frequency of normotension was significantly different between the two guidelines. Compared to the whole study group, the proportion of normotensive adolescents decreased in obese patients, and we think that this leads to a better agreement between the two guidelines observed in obese patients.

Study limitations

This study has some limitations to be mentioned. First, the study group was comprised of adolescents who were suspected to have HT. It did not consist of a homogeneous group that would have been required to conclude community characteristics and screening of patients. Therefore, the frequency of HT is higher than in other studies. Besides, all data were drawn from a single centre; larger-scale and multicentre studies are needed. Despite these limitations, this study compared two hypertension guidelines with different approaches for adolescents aged ≥ 13 and < 16 years ages, including the use of ABPM; thereby providing important evidence for the agreement between the two guidelines.

Conclusion

Both the AAP₂₀₁₇ and the ESHG₂₀₁₆ guidelines can be used in the diagnosis of HT, taking into account the centre experience, and both guidelines have a signed agreement. However, it should be remembered that there is a possible increase in the likelihood of identifying elevated blood pressure and stage 1 HT in the AAP₂₀₁₇ group. Also, the number of adolescents with WCT was higher when the AAP₂₀₁₇ guideline was employed. Even though these differences were identified with our results, there is a need for further research on this subject, and a cautious suggestion would be that physicians should first aim to identify children in risk groups and follow these patients regularly; when a diagnostic evaluation is indeed required, clinicians may benefit from utilising the guideline with which they have higher experience, especially because the agreement levels between these two approaches seem to be very high.

Acknowledgements. None.

Conflicts of interest. None.

Authorship contributions. Concept – G.K.A., Ç.S.D.; Design – G.K.A., Ç.S.D.; Supervision – Ç.S.D.; Fundings – None; Materials – G.K.A., Ç.S.D., N.S.K.; Data collection and/or processing – G.K.A., Ç.S.D.; Analysis and/or interpretation – G.K.A., D.Y.; Literature search – G.K.A., Ç.S.D.; Writing – G.K.A.; Critical review – Ç.S.D.

References

1. Berenson GS, Srinivasan SR, Bao W, et al. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. *N Engl J Med* 1998; 338: 1650–1656. DOI 10.1056/NEJM199806043382302.
2. Daniels SR. Understanding the global prevalence of hypertension in children and adolescents. *JAMA Pediatr* 2019; 173: 1133–1134.

3. Song P, Zhang Y, Yu J, et al. Global prevalence of hypertension in children: a systematic review and meta-analysis. *JAMA Pediatr* 2019; 173: 1154–1163.
4. Larkins NG, Teixeira-Pinto A, Craig JC. The prevalence and predictors of hypertension in a National Survey of Australian Children. *Blood Press* 2018; 27: 41–47. DOI [10.1080/08037051.2017.1380502](https://doi.org/10.1080/08037051.2017.1380502).
5. Lurbe E, Agabiti-Rosei E, Cruickshank JK, et al. European Society of Hypertension guidelines for the management of high blood pressure in children and adolescents. *J Hypertens* 2016; 34: 1887–1920. DOI [10.1097/HJH.0000000000001039](https://doi.org/10.1097/HJH.0000000000001039).
6. Flynn JT, Kaelber DC, Baker-Smith CM, et al. Clinical practice guideline for screening and management of high blood pressure in children and adolescents. *Pediatrics* 2017; 140: e20171904.
7. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. *Pediatrics* 2004; 114: 555–576.
8. Neyzi O, Bundak R, Gökçay G, et al. Reference values for weight, height, head circumference, and body mass index in Turkish children. *J Clin Res Pediatr Endocrinol* 2015; 7: 280–293.
9. Parati G, Stergiou G, O'Brien E, et al. European Society of Hypertension practice guidelines for ambulatory blood pressure monitoring. *J Hypertens* 2014; 32: 1359–1366. DOI [10.1097/HJH.0000000000000221](https://doi.org/10.1097/HJH.0000000000000221).
10. Wühl E, Witte K, Soergel M, et al. Distribution of 24-h ambulatory blood pressure in children: normalized reference values and the role of body dimensions. *J Hypertens* 2002; 20: 1995–2007. DOI [10.1097/00004872-200210000-00019](https://doi.org/10.1097/00004872-200210000-00019).
11. Halbach S. Practical application of ABPM in the pediatric nephrology clinic. *Pediatr Nephrol* 2019; 10: 2067–2076. DOI [10.1007/s00467-019-04361-0](https://doi.org/10.1007/s00467-019-04361-0).
12. Flynn JT, Daniels SR, Hayman LL, et al. Update: ambulatory blood pressure monitoring in children and adolescents: a scientific statement from the American Heart Association. *Hypertension* 2014; 63: 1116–1135.
13. McHugh ML. Interrater reliability: the kappa statistic. *Biochem Med (Zagreb)* 2012; 22: 276–282.
14. Alberg AJ, Park JW, Hager BW, et al. The use of "overall accuracy" to evaluate the validity of screening or diagnostic tests. *J Gen Intern Med* 2004; 19: 460–465.
15. Lurbe E, Torró I, Álvarez J, et al. Impact of ESH and AAP hypertension guidelines for children and adolescents on office and ambulatory blood pressure-based classifications. *J Hypertens* 2019; 37: 2414–2421.
16. Sharma AK, Metzger DL, Rodd CJ. Prevalence and severity of high blood pressure among children based on the 2017 American Academy of Pediatrics Guidelines. *JAMA Pediatr* 2018; 172: 557–565.
17. Bell CS, Samuel JP, Samuels JA. Prevalence of hypertension in children. *Hypertension* 2019; 73: 148–152. DOI [10.1161/HYPERTENSIONAHA.118.11673](https://doi.org/10.1161/HYPERTENSIONAHA.118.11673).
18. Dong Y, Ma J, Song Y, et al. Secular trends in blood pressure and overweight and obesity in Chinese boys and girls aged 7 to 17 years from 1995 to 2014. *Hypertension* 2014; 72: 298–305. DOI [10.1161/HYPERTENSIONAHA.118.11291](https://doi.org/10.1161/HYPERTENSIONAHA.118.11291).
19. Cho H, Kim JH. Secular trends in hypertension and elevated blood pressure among Korean children and adolescents in the Korea National Health and Nutrition Examination Survey 2007–2015. *J Clin Hypertens (Greenwich)* 2020; 22: 590–597. DOI [10.1111/jch.13842](https://doi.org/10.1111/jch.13842).
20. Sook LW, Sablihan NI, Ismail S, Devaraj NK, Mooi CS. Factors associated with the level of physical activities among non-academic staffs in the Faculty of Medicine and Health Sciences of a public university in Selangor, Malaysia. *Mal J Med Health Sci* 2019; 15: 47–55.
21. Çelmeli G, Çürek Y, Arslan Gülten Z, et al. Remarkable increase in the prevalence of overweight and obesity among school-age children in Antalya, Turkey, between 2003 and 2015. *J Clin Res Pediatr Endocrinol* 2019; 11: 76–81.
22. Di Bonito P, Valerio G, Pacifico L, et al. Impact of the 2017 blood pressure guidelines by the American Academy of Pediatrics in overweight/obese youth. *J Hypertens* 2019; 37: 732–738.
23. Dong Y, Song Y, Zou Z, et al. Updates to pediatric hypertension guidelines: influence on the classification of high blood pressure in children and adolescents. *J Hypertens* 2019; 37: 297–306. DOI [10.1097/HJH.0000000000001903](https://doi.org/10.1097/HJH.0000000000001903).
24. Halbach SM, Hamman R, Yonekawa K, Hanevold C. Utility of ambulatory blood pressure monitoring in the evaluation of elevated clinic blood pressures in children. *J Am Soc Hypertens* 2016; 10: 406–412. DOI [10.1016/j.jash.2016.02.013](https://doi.org/10.1016/j.jash.2016.02.013).
25. Kavey RE, Kveselis DA, Atallah N, Smith FC. Whitecoat hypertension in childhood: evidence for an end-organ effect. *J Pediatr* 2007; 150: 491–497. DOI [10.1016/j.jpeds.2007.01.033](https://doi.org/10.1016/j.jpeds.2007.01.033).
26. Venettacci O, Larkins NG. Controversy and agreement among guidelines defining ambulatory hypertension in children. *Kidney Int Rep* 2020; 5: 569–571. DOI [10.1016/j.ekir.2020.02.1032](https://doi.org/10.1016/j.ekir.2020.02.1032).
27. Mancía G, Facchetti R, Grassi G, Bombelli M. Adverse prognostic value of persistent office blood pressure elevation in white coat hypertension. *Hypertension* 2015; 66: 437–444. DOI [10.1161/HYPERTENSIONAHA.115.05367](https://doi.org/10.1161/HYPERTENSIONAHA.115.05367).
28. Seven SS, Niiranen TJ, Kantola IM, Jula AM. White-coat and masked hypertension as risk factors for progression to sustained hypertension: the Finn-Home study. *J Hypertens* 2016; 34: 54–60. DOI [10.1097/HJH.0000000000000750](https://doi.org/10.1097/HJH.0000000000000750).